Sabrina Johnson

Role: President and CEO at Daré Bioscience, Inc
Location: San Diego, CA, US
LinkedIn followers: 500 followers

General Business & ManagementView LinkedIn profile

About Sabrina Johnson

I am committed to meaningfully improving the lives of women. I founded Daré Bioscience in…

Experience

President and CEO
Daré Bioscience, Inc
May 2015 — Present
Daré Bioscience is a biopharmaceutical company committed to the advancement of innovative products for women’s reproductive health. We are driven by a mission to identify, develop and bring to market a diverse portfolio of novel therapies that expand treatment options, improve outcomes and facilitate convenience for women. We are initially focused on the areas of contraception, vaginal health, sexual health, and fertility. DARÉ - Delivering innovation by daring to be different. Biotechnology for women, by women.

Skills

Pharmaceutical Industry
Capital Formation
Strategic Planning
Clinical Development
Lifesciences
Chief Financial Officer
Mergers & Acquisitions
Marketing Strategy
Mergers
Investor Relations
Acquisitions
Commercialization
Strategic Partnerships
Biotechnology
Medical Diagnostics
Leadership
Sales Management
Business Development
Chief Operating Officer

Contact information

Verified work emails, personal emails, and direct dials — unlocked in one click.

Work email
s•••••••@darebioscience.com
Personal email
•••••@•••••.com
Direct dial
+18•••••••83

Unlock verified contacts

Free to start · No credit card required

Current company

Daré Bioscience, Inc

Biotechnology Research · 27 employees · Founded 2015 · San Diego, California, United States

Daré Bioscience® (NASDAQ: DARE) is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women\'s health. With eight potentially first-in-class women’s health products in development, we are committed to bring to market differentiated products designed to expand treatment options, improve outcomes, and facilitate a better quality of life for women. Vaginal drug delivery is often the optimum delivery approach to achieve these objectives, and IVR technology has become one of our preferred investigational platforms. Our portfolio features innovative IVR technologies including our non-hormonal contraceptive Ovaprene®, which we believe has the potential to disrupt the contraceptive landscape by providing protection for one month, without the use hormones, and our suite of ethylene-vinyl acetate (EVA) matrixed IVRs that can provide flexibility in terms of drug loading, drug delivery, and modulation of release rates across a wide array of molecules, hormones, peptides and proteins, facilitating new indications and applications of the technology. Daré’s EVA IVR technology includes DARE-HRT1 for dual hormone replacement as a potential treatment for the vasomotor symptoms of menopause and DARE-FRT1 for vaginal progesterone delivery in support of fertility and the prevention of pre-term birth. In addition to its novel IVR technologies, Daré is developing a topical formulation of sildenafil, the active ingredient in the blockbuster product Viagra®, for the treatment of female sexual arousal disorder (FSAD) as well as a novel vaginal formulation of the selective estrogen receptor modulator (SERM) tamoxifen to address and alleviate the symptoms of vulvar vaginal atrophy (VVA) for women diagnosed with and treated for hormone-receptor-positive (HR+) breast cancer.

darebioscience.com

Find verified contacts for anyone on LinkedIn

Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.

Start for free See how it works

Free plan included · No credit card required

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.

About Sabrina Johnson

Experience

President and CEO

Skills

Find verified contacts for anyone on LinkedIn